Key Highlights OPGx-BEST1 targets BEST1-associated inherited retinal diseases, including BVMD and ARB AAV-based gene therapy approach designed to deliver a functional BEST1 gene directly to retinal pigment epithelium cells Five participants enrolled in Cohort 1, including three with BVMD and two with ARB Four participants have been dosed, with the fifth scheduled for dosing this month Dominant BEST disease participants underwent in vitro confirmation to assess whether their mutations are amenable to gene augmentation Early sentinel participant data showed positive tolerability and biological activity after subretinal administration Three-month topline Cohort 1 data expected in September 2026 For BEST1-associated diseases, careful patient selection, mutation-specific validation, and multi-endpoint retinal assessments may be key to advancing gene augmentation strategies

Gleichzeitig wird es als Kombi-Produkt mit Omega-3-Fettsuren, Magnesium oder Vitaminen angeboten sowie als Zusatz in Eiweishakes und Kohlenhydratgelen
Easy as 1 2 3 Ready Med makes it easy to get started with our $99 FIRST month and then $199 EVERY month, no insurance required, Semaglutide weight management program
Weight loss medications approved by the FDA include GLP-1 receptor agonist drugs, such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)
[DOI] [PubMed] [Google Scholar] 221.Kluth D, Banning A, Paur I, Blomhoff R, Brigelius-Floh R